New Launch2 Jun 2025, 07:31 pm
Biocon Limited gets approval for diabetes drug Liraglutide in India
AI Summary
Biocon Limited has received approval in India for its Liraglutide drug substance. Its subsidiary, Biocon Pharma Limited, has also received approval for its Liraglutide drug product. The approval is for the generic version of Victoza®, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus in adults, adolescents and children aged 10 years and above. The approval was received from the CDSCO under the 101 route that enables recognition of approvals granted by established and referenced serious regulatory authorities.
Key Highlights
- Biocon Limited receives approval for Liraglutide drug substance in India
- Biocon Pharma Limited receives approval for Liraglutide drug product in India
- Generic version of Victoza® approved for treatment of Type 2 Diabetes Mellitus in adults, adolescents and children aged 10 years and above
- Approval received under the 101 route from CDSCO
- Biocon committed to expanding access to GLP-1 therapies